Journal DOI 10.68956/dyh5-kwte

Creative Commons source reading · ALS and frontotemporal degeneration

Serum neurofilament light chain protein is a measure of disease intensity in frontotemporal dementia.

Jonathan D Rohrer; Ione O C Woollacott; Katrina M Dick; Emilie Brotherhood; Elizabeth Gordon; Alexander Fellows; Jamie Toombs; Ronald Druyeh; M Jorge Cardoso; Sebastien Ourselin; Jennifer M Nicholas; Niklas Norgren; Simon Mead; Ulf Andreasson; Kaj Blennow; Jonathan M Schott; Nick C Fox; Jason D Warren; Henrik Zetterberg

Originally published in Neurology · 2016-08-31

From the article

Selected source text. JournalOS removes markup and shortens excerpts where indicated. The full article provides the complete context.

Abstract

Objective To investigate serum neurofilament light chain (NfL) concentrations in frontotemporal dementia (FTD) and to see whether they are associated with the severity of disease. Methods Serum samples were collected from 74 participants (34 with behavioral variant FTD [bvFTD], 3 with FTD and motor neuron disease and 37 with primary progressive aphasia [PPA]) and 28 healthy controls. Twenty-four of the FTD participants carried a pathogenic mutation in C9orf72 (9), microtubule-associated protein tau (MAPT; 11), or progranulin (GRN; 4). Serum NfL concentrations were determined with the NF-Light kit transferred onto the single-molecule array platform and compared between FTD and healthy controls and between the FTD clinical and genetic subtypes. We also assessed the relationship between NfL concentrations and measures of cognition and brain volume. Results Serum NfL concentrations were higher in patients with FTD overall (mean 77.9 pg/mL [SD 51.3 pg/mL]) than controls (19.6 pg/mL [SD 8.2 pg/mL]; p Conclusions Increased serum NfL concentrations are seen in FTD but show wide variability within each clinical and genetic group.

METHODS

Seventy-four participants were consecutively recruited from the University College London FTD study: 34 participants with bvFTD according to Rascovsky criteria,17 3 participants with FTD-MND,18 and 37 participants with PPA according to the Gorno-Tempini criteria.19 Of the 37 PPA participants, 13 had the nonfluent variant (nfvPPA), 10 had the semantic variant (svPPA), 7 had the logopenic variant (lvPPA), and 7 did not fit criteria for any of the 3 variants (PPA-NOS, not otherwise specified).

RESULTS

Serum NfL concentrations in the control and total FTD groups and in each clinical subgroup are shown in table 1. The lowest serum NfL concentration in the study (7.2 pg/mL) was well above the lower limits of detection and quantification of the assay. Serum NfL concentrations were significantly higher in the total FTD group vs controls (mean 77.9 pg/mL [SD 51.3 pg/mL] and 19.6 pg/mL [SD 8.2 pg/mL] respectively; mean difference = 58.3 pg/mL, 95% confidence interval 45.4–71.1; p < 0.001). In distinguishing FTD from controls, a cutoff of 33 pg/mL gave a sensitivity of 84% and specificity of 96%.

DISCUSSION

Using an ultrasensitive immunoassay, we show that serum NfL concentrations are raised in FTD and that higher concentrations are associated with faster rates of brain atrophy. These findings suggest that serum NfL concentrations reflect the intensity of the disease in FTD and that higher concentrations are associated with a more rapid disease progression.

Editorial reading guide

  • Was the evidence cross-sectional, longitudinal or experimental?
  • How did the authors account for age, disease stage and differences among participants?